All In Biotech

Drug Trial Radar · NCT05554406

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7 + 3) vs (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Patients Aged 59 or Younger Who Are Considered High-Risk (Adverse) Acute Myeloid Leukemia As Determined by MYELOMATCH; A MYELOMATCH SubStudy

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 335 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

335

Planned (sponsor's estimate)

Start

Sep 25, 2024

Primary completion

Mar 31, 2027

Study completion Mar 31, 2027

Sponsor

Sponsor type
NIH
First posted
Sep 26, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 59 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with high risk acute myeloid leukemia (AML): 1) daunorubicin and cytarabine liposome alone; 2) cytarabine and daunorubicin with venetoclax; 3) azacitidine and venetoclax; 4) daunorubicin and cytarabine liposome and venetoclax. "High-risk" refers to traits that have been known to make the AML harder to treat. Cytarabine is in a class of medications called antimetabolites. It works by slowing or stopping the growth of cancer cells in the body. Daunorubicin is in a class of medications called anthracyclines. It also works by slowing or stopping the growth of cancer cells in the body. Azacitidine is in a class of medications called demethylation agents. It works by helping the bone marrow to produce normal blood cells and by killing abnormal cells. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. There is evidence that these newer experimental treatment regimens may work better in getting rid of more AML compared to the standard approach of cytarabine and daunorubicin.

Conditions

  • Acute Myeloid Leukemia
  • Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm
  • Acute Myeloid Leukemia Post Cytotoxic Therapy
  • Acute Myeloid Leukemia, Myelodysplasia-Related

Interventions

  • AzacitidineDrug

    Given SC or IV

  • Biospecimen CollectionProcedure

    Undergo collection of blood

  • Bone Marrow AspirationProcedure

    Undergo bone marrow aspiration

  • CytarabineDrug

    Given IV

  • Daunorubicin HydrochlorideDrug

    Given IV

  • Echocardiography TestProcedure

    Undergo ECHO

  • Liposome-encapsulated Daunorubicin-CytarabineDrug

    Given IV

  • Multigated Acquisition ScanProcedure

    Undergo MUGA

  • VenetoclaxDrug

    Given PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Minimal residual disease (MRD) response (Arm 1, 2, 4 and 5)Time frame: After induction (28 days) or re-induction (56 days)
  2. MRD response (Arm 3)Time frame: After two cycles of therapy (56 days)

Locations

227 sites in 3 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama · Recruiting

  • Mayo Clinic Hospital in Arizona

    Phoenix, Arizona · Recruiting

  • Banner University Medical Center - Tucson

    Tucson, Arizona · Recruiting

  • University of Arizona Cancer Center-North Campus

    Tucson, Arizona · Recruiting

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas · Recruiting

  • Alta Bates Summit Medical Center-Herrick Campus

    Berkeley, California · Active not recruiting

  • Cedars-Sinai Medical Center

    Los Angeles, California · Recruiting

  • Kaiser Permanente-Oakland

    Oakland, California · Recruiting

  • Kaiser Permanente-Roseville

    Roseville, California · Recruiting

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California · Recruiting

  • UCSF Medical Center-Parnassus

    San Francisco, California · Recruiting

  • Mills Health Center

    San Mateo, California · Active not recruiting

  • Kaiser Permanente Medical Center - Santa Clara

    Santa Clara, California · Recruiting

  • Yale University

    New Haven, Connecticut · Recruiting

  • Mayo Clinic in Florida

    Jacksonville, Florida · Recruiting

  • Miami Cancer Institute

    Miami, Florida · Recruiting

  • Memorial Hospital West

    Pembroke Pines, Florida · Recruiting

  • Phoebe Putney Memorial Hospital

    Albany, Georgia · Recruiting

  • Augusta University Medical Center

    Augusta, Georgia · Recruiting

  • Hawaii Cancer Care - Westridge

    ‘Aiea, Hawaii · Recruiting

  • Pali Momi Medical Center

    ‘Aiea, Hawaii · Recruiting

  • Hawaii Cancer Care Inc - Waterfront Plaza

    Honolulu, Hawaii · Recruiting

  • Straub Clinic and Hospital

    Honolulu, Hawaii · Recruiting

  • Kapiolani Medical Center for Women and Children

    Honolulu, Hawaii · Recruiting

  • Saint Alphonsus Cancer Care Center-Boise

    Boise, Idaho · Recruiting

  • Saint Luke's Cancer Institute - Boise

    Boise, Idaho · Recruiting

  • Saint Alphonsus Cancer Care Center-Caldwell

    Caldwell, Idaho · Recruiting

  • Kootenai Health - Coeur d'Alene

    Coeur d'Alene, Idaho · Recruiting

  • Saint Luke's Cancer Institute - Fruitland

    Fruitland, Idaho · Recruiting

  • Saint Luke's Cancer Institute - Meridian

    Meridian, Idaho · Recruiting

  • Saint Alphonsus Cancer Care Center-Nampa

    Nampa, Idaho · Recruiting

  • Saint Luke's Cancer Institute - Nampa

    Nampa, Idaho · Recruiting

  • Kootenai Clinic Cancer Services - Post Falls

    Post Falls, Idaho · Recruiting

  • Kootenai Clinic Cancer Services - Sandpoint

    Sandpoint, Idaho · Recruiting

  • OSF Saint Joseph Medical Center

    Bloomington, Illinois · Recruiting

  • Illinois CancerCare-Bloomington

    Bloomington, Illinois · Recruiting

  • Illinois CancerCare-Canton

    Canton, Illinois · Recruiting

  • Illinois CancerCare-Carthage

    Carthage, Illinois · Recruiting

  • Northwestern University

    Chicago, Illinois · Recruiting

  • University of Chicago Comprehensive Cancer Center

    Chicago, Illinois · Recruiting

Showing 40 of 227 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.